Posted in Clinical Data MSD, Eisai report setback in first-line kidney cancer trial April 21, 2026 Pharmaphorum The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma. Clinical DataOncologyRead full story